Appendix for "Development and validation of a dynamic 48-hour in-hospital mortality risk stratification for COVID-19 in a UK teaching hospital: a retrospective cohort study" by Wiegand et al (2022)

**eAppendix 1.** Diagnostic testing used either a real-time reverse transcription polymerase chain reaction (RT-PCR) of the RdRp gene from a nasopharyngeal swab, or the SAMBA II point-of-care test used at the hospital<sup>e1</sup>. Clinical diagnosis of COVID-19 was identified using International Classification of Diseases 10th Edition (ICD-10) codes in the EHR.

## eAppendix 2.

These studies were the TACTIC-E and TACTIC-R trials (ISRCTN11188345 https://doi.org/10.1186/ISRCTN11188345), the REMAP-CAP platform trial for intensive care patients (ISRCTN67000769 https://doi.org/10.1186/ISRCTN67000769), and the RECOVERY trial (ISRCTN50189673 https://doi.org/10.1186/ISRCTN50189673).

### eAppendix 3.

For patients for whom a CFS score had not been recorded by the treating team, a consultant or specialist registrar in Geriatric Medicine reviewed the clinical records and assigned a CFS score using only information recorded at the time of admission<sup>e2</sup>. This approach has been shown to have good agreement with CFS scores assigned after face to face assessment (inter-rater reliability kappa 0.84)<sup>e3</sup>.

# eAppendix 4.

The following keywords were used to identify potentially relevant medical notes: end of life, end-of-life, supportive care, EOL anticipatory med, palliative, comfort care, end of his life, end of her life, terminal wean.

#### eAppendix 5.

Let  $k_i \in \{0,...,n_k\}$  be the event type of patient i, so that  $T_{i,k}$  is patient i's corresponding event time. The probability of patient i with covariates X(s) not experiencing any event before landmark s, and incurring event k within time  $t \in [0,w]$  of this landmark can therefore be calculated by:

$$\mathbb{P}(T_{i,k} < s + t | T_{i,k} \ge s, k_i = k, X(s)) = 1 - exp(-\int_{[0,\tilde{t}]} \lambda(u|X(s))du)$$

Here  $\lambda(t|X(s))$  is the sub-distribution hazard function for event k:

$$\lambda(t|X(s)) = \lambda_{k0}(t) \exp(\beta^T X(s)),$$

with the subdistribution baseline hazard  $\lambda_{k0}(t)$  for event k at time  $t \in [0, w]$ . We report estimated values for  $\beta$  in Table 2. We report in eTable 3 the estimated cumulative baseline sub-distribution hazard function  $\int_{[0,t]} \lambda_{k0}(u) \ du$ , and in eTable 6 and eTable 8 for the sensitivity analyses.

To derive the 48-hour mortality probability ( $k_i = k_{mort}$ , w = 48h) from the Fine-Gray model, we therefore compute the probability of the mortality occurring between the landmarking time s and the end of the prediction horizon s+w, given the patient did not have any event prior to the landmark and accounting for the covariates X(s) collected at the landmark time s.

$$\mathbb{P}(T_{i,k} < s + w | T_{i,k} \ge s, k_i = k_{mort}, X(s)) = 1 - exp(-\int_{[0,w]} \lambda(t | X(s)) dt)$$

To allow for easier access a web-app is available on <a href="http://shiny.mrc-bsu.cam.ac.uk/apps/covid19mortalityrisk/">http://shiny.mrc-bsu.cam.ac.uk/apps/covid19mortalityrisk/</a> that calculates the 48-hour mortality probability based on user input.

## **eReferences**

- [e1] Assennato SM, Ritchie AV, Nadala C, et al. Performance Evaluation of the SAMBA II SARS-CoV-2 Test for Point-of-Care Detection of SARS-CoV-2. J Clin Microbiol 2020; 59(1): e01262-20. http://doi.org/10.1128/JCM.01262-20.
- [e2] Osuafor, CN, Davidson C, Mackett AJ, et al. Clinical Features, Inpatient Trajectories and Frailty in Older Inpatients with COVID-19: A Retrospective Observational Study. *Geriatrics* 2021; 6(1): 11. <a href="http://doi.org/10.3390/geriatrics6010011">http://doi.org/10.3390/geriatrics6010011</a>
- [e3] Marincowitz C, Turner V, Allgar V, et al. Can Patient Frailty Be Estimated from Inpatient Records? A Prospective Cohort Study. *Adv Geriatr Med Res.* 2020; 2(1): e200004. https://doi.org/10.20900/agmr20200004

**eTable 1**. Complete list of candidate predictors, summary statistics and missingness for the development dataset.

Marker Unit		Summary measure/coding	Summary across landmark times <sup>a</sup>	Missingness across landmark times <sup>b</sup>	
Demographics					
Age at	Years		69 [55,81]	- (0%)	
presentation					
		<45	517(7.6%)	_	
		<50	853 (12.5%)	_	
		<55	1386 (20.2%)	_	
		<60	2164 (31.6%)	_	
		<65	2779 (40.6%)	_	
		<70	3371 (49.2%)	_	
		<75	4284 (62.6%)	_	
		<80	5236 (76.5%)	_	
		<85	5857 (85.6%)	_	
		<90	6315 (92.3%)	_	
		<95	6670 (97.4%)	_	
Sex	Female/ Male		41.4% / 58.6%	- (0%)	
Ethnicity		Not included			
White	eyes/no	White British/ White Irish/ Other White background	5215 (76.2%)	<b>–</b> (16.3%)	
Asiar	yes/no	Asian Indian/ Asian Pakistani/ Asian Bangladeshi/ Other Chinese/ Other Asian background	225 (3.3%)	<b>–</b> (16.3%)	
Black	(yes/no	Black Carribean/ Black African/	155 (2.3%)	<b>–</b> (16.3%)	

	Other Black		
	background		
yes/no	Other ethnic group/	137 (2.0%)	<b>–</b> (16.3%)
	Mixed White and		
	Black Carribean/		
	Mixed White and		
	Black African/		
	Mixed White and		
	Asian/ Other mixed		
	background		
kg/m²	Not included	27.3 [22.5, 30.3]	- (6.1%)
kg/m²	18.5 - (Most recent	93.5% = 0	<b>–</b> (6.1%)
	BMI), or 0 if most	After excluding zero: 1.4	
	recent BMI above	[0.5, 1.9]	
	18.5		
Overweightkg/m <sup>2</sup>		38% = 0	- (6.1%)
	25, or 0 if most	After excluding zero: 4.4	
	recent BMI below	[2.3, 9.1]	
	25		
	Value	5 [3, 6]	- (54.5%)
	Documented		
yes/no		780 (11.4%)	
		2=2 (= 22()	
yes/no		353 (5.2%)	
yes/no		1233 (18.0%)	
yes/no		1260 (18.4%)	]
	instory of		
	xg/m² xg/m² xg/m² yes/no yes/no yes/no	background  yes/no  Other ethnic group/ Mixed White and Black Carribean/ Mixed White and Black African/ Mixed White and Asian/ Other mixed background  kg/m²  Not included  kg/m²  18.5 - (Most recent BMI), or 0 if most recent BMI above 18.5  kg/m²  (Most recent BMI) - 25, or 0 if most recent BMI below 25  Value  yes/no  Documented history of yes/no  Documented history of  Documented history of  Documented history of  Documented history of	background  Other ethnic group/ Mixed White and Black Carribean/ Mixed White and Black African/ Mixed White and Asian/ Other mixed background  Og/m²  Not included  Og/m²  18.5 - (Most recent BMI), or 0 if most recent BMI above 18.5  Og/m²  (Most recent BMI) - 25, or 0 if most recent BMI below 25  Value  5 [3, 6]  Value  5 [3, 6]  Ocumented history of yes/no Documented Documented history of yes/no Documented Documented history of yes/no Documented Do

Hypertension	yes/no	Documented history of	2193 (32.0%)	-
Immunocompro mised	yes/no	Documented history of	80 (1.1%)	-
Chronic liver disease	yes/no	Documented history of	640 (9.4%)	-
Non-haematolo gical malignancy	yes/no	Documented history of	576 (8.4%)	_
Haematological malignancy	yes/no	Documented history of	284 (4.1%)	-
Chronic kidney disease	yes/no	Documented history of	502 (7.3%)	-
Respiratory disease	yes/no	Documented history of	833 (12.2%)	-
Stroke	yes/no	Documented history of	220 (3.2%)	-
Observations				
Heart rate (HR)	Beats/min	24h mean	83 [73, 93]	17.3 (0.0%)
		24h min	72 [63, 82]	
		24h max	94 [83, 106]	
		Trend	0 [-4.5, 4]	- (6.3%)
Mean arterial	mmHg	24h mean	86 [79, 94]	17.1 (0.0%)
pressure		24h min	74 [66, 83]	
		24h max	100 [91, 109]	
		Trend	0.0 [-0.4, 0.4]	<b>–</b> (6.3%)
Temperature	Degrees	24h mean	37.0 [36.7, 37.3]	9.3 (0.0%)
	Celsius	24h min	36.4 [36.1, 36.7]	

		24h max	37.5 [37.1, 38.1]	
		Trend	0 [-0.3, 0.2]	- (6.3%)
Respiratory Rate	Breaths/min	24h mean	18.5 [17, 21]	18.8 (0.0%)
(RR)		24h min	16 [15, 18]	
		24h max	20 [19, 26]	
		Trend	0 [-1,1]	- (6.3%)
SpO2/FiO2 ratio		24h mean	431 [325, 456]	12.8 (0.0%)
		24h min	392 [250, 448]	
		24h max	457 [443, 467]	
		Trend	0 [-7.0, 7.4]	- (6.3%)
P/F ratio	mmHg	24h mean	184 [136, 250]	1.5 (77.9%)
		24h min	140 [98, 201]	
		24h max	229 [171, 310]	
		Trend	2 [-18, 24]	- (80.3%)
Glasgow coma	Lowest	<9	33.8%	_
scale (GCS)	GCS in the	<12	47.0%	<u> </u>
	last 24h			
Laboratory tests				
Urea	mmol/L	Most recent	8.8 [5.6, 14.1]	0.9 (38.0%)
		measurement		
		during last 48h		
Creatinine	μmol/L	Most recent	70 [52, 106]	0.9 (25.8%)
		measurement		
		during last 48h		
		Trend	-1 [-7, 4]	- (43.4%)
Sodium	mmol/L	Not included	138.6 [135.5, 142]	2.7 (24.8%
		Trend	0.0 [-1.0, 1.5]	- (41.9%)
Hyponatraemia	Na < 135	135 - (lowest	82% = 0	2.7 (24.8%)
	mmol/L	sodium during last	After excluding zero: 2 [1,	
		24h), or 0 if all	4]	
		above 135		

Hypernatraemia	aNa > 145	(highest sodium	85.2% = 0	
	mmol/L	during last 24h) -	After excluding zero: 3.8	
		145, or 0 if all	[2, 6.2]	
		below 145		
Potassium	mmol/L	Most recent	4.1 [3.7, 4.4]	2.7 (25.0%)
		measurement		
		during last 24h		
		Trend	0 [-0.2, 0.2]	- (42.1%)
Albumin	g/L	Most recent	24 [20, 28]	1.2 (33.6%)
		measurement		, ,
		during last 48h		
Alanine	U/L	Most recent	36 [22, 61]	0.7 (37.2%)
Transaminase		measurement		
(ALT)		during last 48h		
Alkaline	U/L	Most recent	100 [73, 149]	2.3 (19.8%)
phosphatase		measurement		
(ALP)	ALP)			
Bilirubin	μmol/L	Most recent		
		measurement	8 [5, 13]	0.7 (37.4%)
		during last 48h		· · · · · · · · · · · · · · · · · · ·
Lactate	U/L	Most recent 335 [261, 436]		0.2 (80.5%)
dehydrogenase		measurement		
(LDH)		during last 48h		
C-reactive protein	mg/L	Most recent	56 [22, 131]	1.6 (12.8%)
(CRP)		measurement		
		during last 48h		
		Trend	0 [-0.2, 0.3]	- (45.9%)
Procalcitonin	ng/ml	Most recent	0.24 [0.08, 0.83]	0.2 (84.4%)
(PCT)		measurement		
		during last 48h		
Ferritin	μg/L	Most recent	726 [336, 1427]	0.3 (76.6%)
		measurement		
		•		

		during last 48h		
Haemoglobin	g/L	Most recent	104 [89, 122]	5.4 (12.4%)
		measurement		
		during last 48h		
		Trend	-1 [-5, 3]	- (43.9%)
White cell count	10º/L	Most recent	7.9 [5.7, 10.6]	1.6 (12.7%)
(WCC)		measurement		
		during last 48h		
		Trend	0 [-1, 1]	<b>– (46.1%)</b>
Neutrophils		Most recent	5.7 [3.9, 8.2]	1.6 (13.4%)
	10 <sup>9</sup> /L	measurement		
		during last 48h		
Lymphocytes	10 <sup>9</sup> /L	Most recent	1.1 [0.7, 1.5]	1.6 (13.4%)
		measurement		
		during last 48h		
Neutrophil-Lymph Ratio		Most recent	5.4 [3.2, 9.5]	1.6 (13.5%)
ocytes rat	io	measurement		
		during last 48h		
Eosinophils	10 <sup>9</sup> /L	Most recent	0.1 [0.02, 0.28]	1.6 (14.1%)
		measurement		
		during last 48h		
Monocytes	10º/L	Most recent	0.45 [0.3, 0.64]	1.6 (13.5%)
		measurement		
		during last 48h		
Platelets	10 <sup>9</sup> /L	Most recent	280 [193, 387]	1.6 (12.8%)
		measurement		
		during last 48h		
		Trend	3 [-17, 26]	- (46.3%)
Red cell	%	Most recent	15.1 [14, 16.4]	1.6 (13.3%)
distribution width	n	measurement		
(RDW)		during last 48h		
Prothrombin Tim	e sec	Most recent	13.3 [12.5, 14.5]	0.84 (52.6%)
		measurement		

		during last 48h		
Activated partial	sec	Most recent	32.3 [29.6, 35.3]	0.84 (53.8%)
thromboplastin		measurement		
time (APTT)		during last 48h		
D-Dimer	ng/ml	Most recent	552 [284, 1677]	0.4 (71.9%)
		measurement		
		during last 48h		
Troponin	ng/L	Most recent	17 [5.6, 48.7]	0.3 (80.5%)
		measurement		
		during last 48h		
Interferon	pg/ml	Most recent	0.9 [0.9, 2.5]	0.2 (84.2%)
Gamma (IG)		measurement		
		during last 48h		
TNF-Alpha	pg/ml	Most recent	12.3 [8.3, 18.2]	0.2 (84.2%)
(TNFA)		measurement		
		during last 48h		
Interleukin-1 beta	pg/ml	Most recent	0.5 [0.3, 0.9]	0.2 (84.2%)
(IL-1)		measurement		
		during last 48h		
Interleukin-6	pg/ml	Most recent	13.6 [4.7, 31.9]	0.3 (84.0%)
(IL-6)		measurement		
		during last 48h		
Interleukin-10	pg/ml	Most recent	1.88 [0.7, 4.4]	0.2 (84.2%)
(IL-10)		measurement		
		during last 48h		
Interleukin ratio	Ratio	Most recent	7.6 [2.9, 20.1]	0.2 (84.3%)
(IL-ratio, IL6	/	measurement		
IL10)	)	during last 48h		
Lactate	mmol/L	Most recent	1.3 [1.0, 1.7]	3.7 (60.4%)
		measurement		
		during last 48h		
	1			

pH – arterial or		Not included	7.41 [7.36, 7.44]	1.9 (66.4%)
(venous + 0.03)				
Acidosis	pH-value <	7.35 - (lowest pH	67.1% = 0	1.9 (66.4%)
	7.35	during last 24h), or	After excluding zero:	
		0 if all above 7.35	0.06 [0.028,0.107]	
Alkalosis	pH-value >	(Highest pH during	66.8%= 0	
	7.45	last 24h) - 7.45, or	After excluding zero:	
		0 if all below 7.45	0.024 [0.011, 0.039]	
Treatments,				
interventions				
and level of care				
Visited ICU	yes/no	During last 24h	1789 (26.1%)	_
Mechanically	yes/no	During last 24h	1420 (20.7%)	_
ventilated				
Cardiovascular	yes/no	During last 24h	705 (10.3%)	_
support				
Renal	yes/no	During last 24h	348 (5.1%)	_
replacement				
therapy				
Steroids (oral or	yes/no	Ever during this	2770 (40.5%)	_
intravenous;		hospital visit up to		
dexamethasone,		now		
hydrocortisone,				
prednisolone,				
methylprednisolo				
ne)				

<sup>&</sup>lt;sup>a</sup> For yes/no items shown as number (%) across landmark times; for quantitative items shown as median [IQR] across landmark times

<sup>&</sup>lt;sup>b</sup> Shown as mean number of measurements per landmark (% landmarks with no measurement)

<sup>c</sup> For 45 patients for whom no CFS score had been recorded by the treating team, a consultant or specialist registrar in Geriatric Medicine reviewed the clinical records and assigned a CFS score using only information recorded at the time of admission.

eTable 2. ICD-10 codes used to identify comorbidities.

Diagnosis	ICD-10	Description	
	codes		
Hypertension	110	Essential hypertension	
	111	Hypertensive heart disease	
	112	Hypertensive renal disease	
	l13	Hypertensive heart and renal disease	
	115	Secondary hypertension	
Diabetes	E10	Type 1 diabetes mellitus	
	E11	Type 2 diabetes mellitus	
	E12	Malnutrition-related diabetes mellitus	
	E13	Other specified diabetes mellitus	
	E14	Other unspecified diabetes mellitus	
Chronic liver disease	K70	Alcoholic liver disease	
	K71	Toxic liver disease	
	K72	Hepatic failure, not elsewhere classified	
	K73	Chronic hepatitis, not elsewhere classified	
	K74	Fibrosis and cirrhosis of the liver	
	K75	Other inflammatory diseases of the liver	
	K76	Other diseases of the liver	
	K77	Liver disorders in disease classified elsewhere	
Asthma	J45	Asthma	
Non-haematological	C0	Malignant neoplasm of lip	
malignancy	C1	Malignant neoplasm of base of tongue	
	C2	Malignant neoplasm of other unspecified parts of	
		tongue	
	C3	Malignant neoplasm of gum	
	C4	Malignant neoplasm of floor of mouth	
	C5	Malignant neoplasm of palate	
	C6	Malignant neoplasm of other and unspecified parts of	
		mouth	
	C7	Malignant neoplasm of parotid gland	

Haematological	C8	Malignant neoplasm of other and unspecified major		
malignancy		salivary glands		
	C9	Malignant neoplasm of tonsil		
Stroke	163	Cerebral infarction		
	165	Occlusion and stenosis of precerebral arteries, not		
		resulting in cerebral infarction		
	166	Occlusion and stenosis of cerebral arteries, not resulting		
		in cerebral infarction		
Chronic kidney disease	N18.1-N18.5	Chronic kidney disease stage 1-5		
	N18.9	Chronic kidney disease, unspecified		
	l13	Hypertensive and renal disease		
Chronic heart disease	120	Angina pectoris		
	121	Acute myocardial infarction		
	122	Subsequent myocardial infarction		
	123	Certain current complications following acute		
		myocardial infarction		
	124	Other acute ischaemic heart diseases		
	125	Chronic ischaemic heart disease		
	134	Nonrheumatic mitral valve disorders		
	135	Nonrheumatic aortic valve disorders		
	136	Nonrheumatic tricuspid valve disorders		
	137	Pulmonary valve disorders		
	142	Cardiomyopathy		
	143	Cardiomyopathy in diseases classified elsewhere		
	144	Atrioventricular and left bundle-branch block		
	150	Heart failure		
Immunocompromised	D80	Immunodeficiency with predominantly antibody defects		
	D81	Combined immunodeficiencies		
	D82	Immunodeficiency associated with other major defects		
	D83	Common variable immunodeficiency		
	D84	Other immunodeficiencies		
Dementia	F01	Vascular dementia		

	F02	Dementia in other diseases classified elsewhere		
	F03	Unspecified dementia		
	G30, G31	Alzheimer disease & Other degenerative diseases of		
		nervous system, not elsewhere classified		
	F10.27	Alcohol dependence, with alcohol-induced persisting		
		dementia		
	F10.97	Alcohol use, unspecified with alcohol-induced persisting		
		dementia		
	F19.97	Other psychoactive substance use, unspecified with		
		psychoactive substance-induced persisting dementia		
Respiratory disease	127	Other pulmonary heart diseases		
	J6*-J7*	Lung diseases due to external agents		
	J41	Simple and mucopurulent chronic bronchitis		
	J42	Unspecified chronic bronchitis		
	J43	Emphysema		
	J44	Other chronic obstructive pulmonary disease		
	J47	Bronchiectasis		

**eTable 3:** Baseline cumulative subdistribution hazards for mortality in the final model, as needed for calculation of the 48 hour survival probabilities (eAppendix 5).

Time after landmark (hours)	Cumulative subdistribut ion hazard	Time after landmark (hours)	Cumulative subdistribut ion hazard	Time after landmark (hours)	Cumulative subdistribut ion hazard	Time after landmark (hours)	Cumulative subdistribut ion hazard
1	0.00094	13	0.00852	25	0.02143	37	0.03339
2	0.00161	14	0.00906	26	0.02339	38	0.03480
3	0.00255	15	0.00942	27	0.02463	39	0.03559
4	0.00304	16	0.00963	28	0.02525	40	0.03582
5	0.00363	17	0.01109	29	0.02673	41	0.03707
6	0.00427	18	0.01140	30	0.02783	42	0.03778
7	0.00458	19	0.01220	31	0.02876	43	0.03867
8	0.00516	20	0.01434	32	0.03008	44	0.04101
9	0.00563	21	0.01563	33	0.03095	45	0.04200
10	0.00713	22	0.01674	34	0.03182	46	0.04322
11	0.00787	23	0.01821	35	0.03265	47	0.04481
12	0.00834	24	0.01962	36	0.03318	48	0.04625

**eTable 4:** Final model coefficients for landmarks less than 28 days from admission (or the first positive SARS-CoV-2 test if infection was nosocomial).

Predictor	Coefficients when recorded	Coefficients if not recorded <sup>1</sup>
Age <75 years, at admission	-0.269	_
Age <80 years, at admission	-0.135	_
Heart rate, beats/min, mean during last 24h	0.00154	_
Respiratory rate, breaths/min, minimum during last 24h	0.135	_
SpO2/FiO2 ratio, minimum during last 24h	-0.0114	_
WCC, 10 <sup>9</sup> /L, most recent measurement during last 48h	0.00169	-0.000359
Acidosis, 7.35 - (lowest pH during last 24h), or 0 if all above 7.35	5.97	1.66

<sup>&</sup>lt;sup>1</sup> If the predictor value is not recorded (due to not being measured or documented in the EHR within the relevant time window), the fixed value in this column is used, and the coefficient corresponding to the predictor value is ignored.

eTable 5. Final model coefficients for model omitting all blood tests.

Predictor	Coefficients when recorded	Coefficients if not recorded <sup>1</sup>
Age <75 years, at admission	-0.683	_
Age <80 years, at admission	-0.195	_
Clinical Frailty Score, at admission	0.193	-0.170
Heart rate, beats/min, mean during last 24h	0.0175	_
Respiratory rate, breaths/min, minimum during last 24h	0.0570	_
SpO2/FiO2 ratio, minimum during last 24h	-0.0125	_

<sup>&</sup>lt;sup>1</sup> If the predictor value is not recorded (due to not being measured or documented in the EHR within the relevant time window), the fixed value in this column is used, and the coefficient corresponding to the predictor value is ignored.

**eTable 6:** Baseline cumulative subdistribution hazards for the alternative model without blood tests, as needed for calculation of the 48 hour survival probabilities (eAppendix 5).

Time after landmark (hours)	Cumulativ e subdistrib ution hazard						
1	0.000687	13	0.006248	25	0.015666	37	0.024447
2	0.00118	14	0.006647	26	0.017095	38	0.02549
3	0.001872	15	0.006911	27	0.018004	39	0.026075
4	0.002229	16	0.007063	28	0.018459	40	0.026245
5	0.002662	17	0.008136	29	0.019544	41	0.027172
6	0.003129	18	0.008366	30	0.020346	42	0.027697
7	0.003357	19	0.008946	31	0.021037	43	0.028356
8	0.003784	20	0.010495	32	0.022007	44	0.030097
9	0.00413	21	0.011433	33	0.022648	45	0.030851
10	0.005232	22	0.012245	34	0.023292	46	0.031778
11	0.005773	23	0.013308	35	0.0239	47	0.032995
12	0.006119	24	0.014341	36	0.024293	48	0.034088

**eTable 7**. Model coefficients for the alternative model with IL-6 replaced by CRP and re-calculating the model coefficients through the same penalised likelihood function used in the SCAD algorithm.

Predictor	Coefficients when recorded	Coefficients if not recorded <sup>1</sup>
Age <75 years, at admission	-0.115	-
Age <80 years, at admission	-0.0582	-
Clinical Frailty Score, at admission	0.0672	0.150
Heart rate, beats/min, mean during last 24h	0.0128	_
Respiratory rate, breaths/min, minimum during last 24h	0.0515	-
SpO2/FiO2 ratio, minimum during last 24h	-0.00346	_
WCC, 10 <sup>9</sup> /L, most recent measurement during last 48h	0.00239	-0.116
Acidosis, 7.35 - (lowest pH during last 24h), or 0 if all above 7.35	2.73	0.474
C-reactive protein, pg/ml, most recent measurement during last 48h	-0.0000350	0.220

<sup>&</sup>lt;sup>1</sup> If the predictor value is not recorded (due to not being measured or documented in the EHR within the relevant time window), the fixed value in this column is used, and the coefficient corresponding to the predictor value is ignored.

**eTable 8**: Baseline cumulative subdistribution hazards for the alternative model with IL-6 replaced by CRP, as needed for calculation of the 48 hour survival probabilities (eAppendix 5).

Time after landmark (hours)	Cumulative subdistribut ion hazard	Time after landmark (hours)	Cumulative subdistribut ion hazard	Time after landmark (hours)	Cumulative subdistribut ion hazard	Time after landmark (hours)	Cumulative subdistribut ion hazard
1	0.00010	13	0.00091	25	0.00224	37	0.00342
2	0.00017	14	0.00097	26	0.00243	38	0.00355
3	0.00028	15	0.00101	27	0.00255	39	0.00363
4	0.00033	16	0.00103	28	0.00262	40	0.00365
5	0.00039	17	0.00118	29	0.00276	41	0.00378
6	0.00046	18	0.00122	30	0.00287	42	0.00384
7	0.00049	19	0.00130	31	0.00296	43	0.00393
8	0.00056	20	0.00152	32	0.00309	44	0.00416
9	0.00061	21	0.00165	33	0.00318	45	0.00425
10	0.00077	22	0.00176	34	0.00326	46	0.00437
11	0.00084	23	0.00191	35	0.00334	47	0.00452
12	0.00089	24	0.00205	36	0.00340	48	0.00466


eTable 9. Final model coefficients for 72 hour prediction horizon

Predictor	Coefficients when recorded	Coefficients if not recorded <sup>1</sup>
Age <75 years, at admission	-0.564	-
Age <80 years, at admission	-0.183	-
History of non-haematological malignancy	0.146	-
Clinical Frailty Score, at admission	0.0721	0.0544
Respiratory rate, breaths/min, minimum during last 24h	0.100	-
SpO2/FiO2 ratio, minimum during last 24h	-0.0111	-
WCC, 10 <sup>9</sup> /L, most recent measurement during last 48h	0.00806	-0.0198ª
Acidosis, 7.35 - (lowest pH during last 24h), or 0 if all above 7.35	1.29	0.0.0898
Platelets, 10 <sup>9</sup> /L, most recent measurement during last 48h	-0.000375	-0.0198ª


<sup>&</sup>lt;sup>a</sup> WCC and Platelets are measured on the same sample, therefore the missingness for both clinical parameters is shared.

<sup>&</sup>lt;sup>1</sup> If the predictor value is not recorded (due to not being measured or documented in the EHR within the relevant time window), the fixed value in this column is used, and the coefficient corresponding to the predictor value is ignored.


**eFigure 1.** Net benefit curve for risk stratification in the training dataset using the proposed model and by classifying either everyone or no-one as high risk patients. The dashed line shows 95% CI.



**eFigure 2.** Net benefit curve for risk stratification in the test dataset using the proposed model and by classifying either everyone or no-one as high risk patients. The dashed line shows 95% CI.



**eFigure 3.** Performance metrics for in-hospital mortality in the training dataset with 72 hour prediction horizon. (A) Receiver operator characteristic plot, with labels indicating the corresponding threshold and the dashed line indicating the line of no discrimination. (B) Precision-recall plot, with the 2.8% observed incidence indicated by the dashed line. (C) Number needed to evaluate against sensitivity. (D) Calibration plot (with 95% CI), by tenths of predicted risk, with the dashed line indicating perfect calibration.



**eFigure 4.** Performance metrics for in-hospital mortality in the test dataset with 72 hour prediction horizon. (A) Receiver operator characteristic plot, with labels indicating the corresponding threshold and the dashed line indicating the line of no discrimination. (B) Precision-recall plot, with the 3.1% observed incidence indicated by the dashed line. (C) Number needed to evaluate against sensitivity. (D) Calibration plot (with 95% CI), by tenths of predicted risk, with the dashed line indicating perfect calibration.

